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Prostate cancer is the second most leading cause of cancer-related death among 
American men. The expression of androgen receptor protein has been established by 
numerous studies as a main driving force for the progression of prostate cancer. In an 
effort to combat this disease, potent compounds such as genistein have been identified to 
have significant anti-cancer activity and androgen receptor modulation in prostate cancer 
cells. Furthermore, studies have shown that antiandrogen ligands may be functionalized 
with hydrophobic moieties to selectively degrade androgen receptor protein in vitro. 
Building upon these findings, this study explores the efficacy of a bifunctional molecule; 
specifically a combination of a potent, non-steroidal enzalutamide-derived antiandrogen 
with genistein acting as a partially hydrophobic degradation tag. Preliminary cell viability 
studies have identified a promising lead compound (compound 9b) within the synthesized 
conjugates. This compound exhibits potent inhibition of cell growth in androgen sensitive 
LNCaP cells (IC50 = 1.44 ± 0.9 µM), and androgen insensitive DU145 cells (IC50 = 3.38 
± 0.9 µM). Western immunoblotting studies confirm the dose-dependent degradation of 
androgen receptor and cell cycle analyses indicate S-phase arrest with the treatment of 
compound 9b. While preliminary immunoblotting studies suggest the degradation of 
androgen receptor is mediated by the ubiquitin protease system, further studies must be 
carried out to validate these preliminary results. Future studies include looking into 
androgen receptor binding efficacy with the addition of the genistein moiety and the 
effect of the target compounds on the metastatic potential of bone-derived (PC3) prostate 







 Among American men, prostate cancer (PCa) is the second most leading cause of 
cancer-related death and accounts for nearly 240,000 new cases each year [1, 2]. AR 
expression has been shown by numerous studies to be vital in prostate cancer cell 
progression [3]. Genistein (Figure 1.3A), a natural soy isoflavone, is among the most 
potent phytogestrogens to have beneficial pharmacological effects in animal cells and 
also exhibit antitumor activity [4]. Genistein has the potential to become a powerful 
therapeutic against prostate cancer due to many properties that work in concert to exhibit 
anti-proliferative activity in cancer cells [4]. Previous studies have primarily focused on 
elucidating the mechanisms by which genistein works to suppress cancer growth [5-10]. 
Recent research in the area of drug design has shown that the incorporation of multiple 
pharmaceutical moieties on a single molecule has the potential to enhance drug efficacy 
and specificity to prostate cancer cells via androgen receptor (AR) binding [11] and the 
subsequent utilization of cellular machinery such as the ubiquitin protease system (UPS) 
to selectively degrade AR protein [12-14]. With regard to these findings, a novel 
pharmaceutical design incorporating genistein may prove to be a potent therapeutic for 









II. THE ROLE OF ANDROGEN RECEPTOR IN PROSTATE CANCER  
The androgen receptor (AR) is involved in the normal function of the prostate and 
other tissues and is important in the progression of PCa [15]. In its unbound state, AR is a 
steroid hormone receptor found in the cytoplasm associated with heat shock proteins 
(HSP-90), cytoskeletal proteins, and other chaperones [16]. After binding to one of its 
natural ligands (dihydroxytestosterone (DHT) or testosterone), AR undergoes a 
conformational change which results in homodimerization, followed by nuclear 
translocation, DNA binding, and the transcription of AR regulated genes [17]. The AR 
regulates gene expression via binding to androgen-response elements (AREs) in 
proximity to genes directly transcribed by the AR [15].  
 For patients with early stage prostate cancer, androgen deprivation therapy (ADT) 
is often employed as a first-line therapy in the form of antiandrogens or luteinizing 
hormone-releasing hormone (LHRH) agonists. While most patients respond well to ADT, 
many of these patients will become refractory to treatment and develop castration 
resistant PCa (CRPC) [18]. Several studies have shown that the frequency of AR 
mutations is higher in CRPC, which draws attention to the role of AR in PCa progression 
[19, 20]. AR mutations have been shown to result in the conversion of several AR 
antagonists (e.g. bicalutamide, nilutamide, enzalutamide) to agonists [21-23] and also 
allow for the receptor to be activated by a broad range of ligands [24-26]. The importance 
of AR expression in CRPC progression is clear as AR expression is nearly 6-fold higher 
in CRPC compared to hormone-sensitive PCa [27]. As such, numerous second-line 
therapies (i.e. enzalutamide, abiraterone) treat CRPC by targeting androgen synthesis 




III. GENISTEIN ACTIVITY 
 Several studies have been performed to characterize the mechanisms that 
genistein uses to inhibit proliferative activity in cancer cells. Cao et. al showed that 
genistein can inhibit the activity of tyrosine receptor kinases (TRKs) and subsequently 
inhibit mitogen activated protein kinase signaling pathways (MAPKs) [8, 31]. Genistein 
actively inhibits the phosphorylation of TRK, thereby inhibiting the TRK signal 
transduction pathway (TRK  Raf MEK  ERK/p38). Sasamura et. al identified the 
anti-proliferative effect of the inhibition of TRK by genistein in human renal cell 
carcinoma [8].  Studies have also shown that genistein can inhibit the NF-kB pathway in 
prostate cancer cells [5, 7]. Li et. al indicated that inhibition of NF-kB by genistein is 
linked to the Akt signaling pathway for cell survival. Immunoprecipitation and kinase 
assays have shown that genistein specifically inhibits Akt kinase activity and also 
epidermal growth factor induced activation of Akt in prostate cancer cells [7]. 
Furthermore, this inhibition was only observed in tumorigenic prostate cancer cells, but 
not prostate epithelial cells [7]. Davis et. al showed that genistein specifically prevents 
NF-kB activation by DNA-damaging agents and also suggested that the inhibition of NF-
kB may be genistein’s mechanism of inducing apoptosis in cancer cells [5].  
In the metastasis of cancer, vascularization is a key step in sustaining tumor 
growth and allowing cancer cells to migrate. Results by Su. et. al, genistein has been 
shown to inhibit angiogenesis in human bladder cancer cells [9]. It was reported that 
genistein exhibited a dose-dependent inhibition of vascular endothelial growth factor 
(VEGF), platelet-derived growth factor, and matrix metalloprotease-2 and 9 (MMP 2 and 
9) [9]. The suppression of MMP 2 and 9 shows that genistein helps to suppress the 
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degradation of the extracellular matrix (ECM) needed for metastasis as well.  It was also 
found that angiogenesis inhibitors such as endostatin, angiostatin, and thrombospodin-1 
were up-regulated [9].  
The development of prostate cancer is often linked to the accumulation of genetic 
and epigenetic modifications that result in the silencing of tumor suppressor genes 
(TSGs). It has been shown that genistein increases the expression of several histone 
acetyltransferases (HATs) in LNCaP and DuPro prostate cancer cell lines as well as 
normal epithelial prostate cancer cells [32]. The increased expression of HATs allow for 
the increased acetylation of histones H3 and H4 which increases the transcription of p21 
and p16, genes that induce  cell cycle arrest and apoptosis [32]. Furthermore, increased 
H3K9 acetylation indicated the re-expression of important tumor suppressor genes such 
as PTEN, p53, CYLD and FOXO3a [33]. Jagadeesh et. al also shows that genistein 
affects telomerase activity [6]. Telomerase activity is essential for cells to gain 
immortality and sustained proliferation as it is responsible for the integrity of the genome. 
Genistein was found to down-regulate the expression of human telomerase reverse 
transcriptase (hTERT) in prostate cancer cells [6].  
Genistein has also been shown to decrease AR protein, mRNA levels, and binding 
to AREs which resulted in the reduction of androgen-mediated transcriptional activation 
of prostate specific antigen (PSA) in androgen-dependent cells [34, 35]. Furthermore, the 
estrogenic activity of genistein downregulates HDAC6-HSP90 chaperone function and 
has been attributed to the increased ubiquitination of AR and subsequent degradation by 
the UPS in PCa cells, thereby decreasing AR protein levels [36].  
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IV. COMBINATORIAL TREATMENTS WITH GENISTEIN 
Combinational therapies have long been used in the treatment of cancer to gain 
increased drug performance. Phillip et. al has shown that genistein cooperates with 
HDAC inhibitor vorinostat to induce apoptosis in prostate cancer cells [37]. A 
combination of the epigenetic effects of genistein (increased HAT1 activity and H3K9 
acetylation) and HDACi led to increased levels of apoptosis via the effective transcription 
of TSGs [37]. Another study by Gryder et. al couples an AR inhibiting nilutamide moiety 
(antiandrogen) with vorinostat to selectively target and accumulate the pharmaceutical in 
prostate cancer cells [11]. This mechanism of action utilizes AR’s affinity for nuclear 
localization (Figure 1.1) to allow vorinostat to accumulate in cancerous cells and induce 
epigenetic modifications while also inhibiting AR.  
 
Figure 1.1 An antiandrogen group binds to AR and is transported to nucleus along 




V. SELECTIVE PROTEIN DEGRADATION AND PHARMACEUTICAL 
DESIGN 
The selective degradation of clinically relevant proteins such as AR represents a 
novel strategy that could offer a direct solution to the progression of PCa. Postulating that 
increased AR protein expression drives the development of CRPC, we pursued a 
bifunctional, pharmaceutical design that would incorporate the cancer killing properties 
of an antiandrogen and genistein, and possibly act as a selective androgen receptor 
degrader (SARD). Various studies have demonstrated that hydrophobic tagging via a 
small, bifunctional molecule is a viable strategy for the post-translational targeting of AR 
and other proteins for degradation [12-14]. An example of a well-characterized SARD is 
given by Figure 1.2. In essence, this hydrophobic tagging simulates a misfolded protein 
which is then processed and degraded by the UPS [14, 38].  
 
Figure 1.2. An example of a SARD as published in a study by Gustafson et. Al [14].  
 
Our design incorporated derivatives of the well-established non-steroidal 
antiandrogens enzalutamide (Figure 1.3B) [28] and RU59063 [39, 40] conjugated to 
genistein via an alkyl or PEG linker (Figure 1.3C). We hypothesize that the 
hydrophobicity of the genistein moiety would emulate a hydrophobic tag conjugated to 
an antiandrogen which would allow for the selective binding to AR protein and 
subsequent degradation by the UPS. Furthermore, the accumulation our bifunctional 
compound in the prostate may allow for the beneficial regulation of several cellular 
pathways via the genistein moiety. 
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Figure 1.3 (A) Structure of genistein, (B) structure of the FDA approved antiandrogen 
enzalutamide (Xtandi®), (C) Design for an enzalutamide-derived antiandrogen-genistein 
compound (X = Oxygen(O) or Sulfur(S)). The PEG linker length is variable to optimize 
























Reagents and Conditions: (A) DMF at 100oC for 12h (B) KI in DMF at 100oC for 12h(C) 
CuI, DIPEA, in DMSO at RT for 2h. 
 
Figure 2.1 Synthetic scheme for target compounds.  
The tetrabutylammonium salt of genistein (1), 2-azidoethyl 4-
methylbenzenesulfonate (2), and PEG-Tosyl-Azide (4) were prepared as previously 
reported in the literature [41-43]. Variable linker lengths were employed to test the 
effects of a short alkyl linker compared to a long, flexible PEG linker. Genistein-alkyl-
azide (3) and genistein-PEG-azide (5) were made via the condensation of (1) with (2) and 
(4), respectively. Subsequent Cu(I) catalyzed Huisgen cycloaddition reactions [44] 
between the azides (3 and 5) and the terminal alkynes on 6, 7, and 8 yielded the desired 
conjugates: 9a-b, 10a-b, and 11a-b. 
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II. CELL CULTURE AND MATERIALS 
LNCaP and DU145 cells were obtained from ATCC (Manassas, VA). MCF-7 was a 
gift from Dr. Al Merrill’s laboratory (Georgia Institute of Technology, Atlanta, GA). Cells 
were routinely cultured in phenol-red free RPMI-1640 (Lonza, Walkersville, MD) for 
LNCaP, EMEM (Quality Biological, Gaithersburg, MD)  for DU145, and DMEM (Corning, 
Manassas, VA) for MCF-7 as per the manufacturer’s suggested protocols with 10% fetal 
bovine serum (FBS) (Atlanta Biologicals, Norcross, GA) and Penicillin/Streptomycin  
(Sigma-Aldrich, St. Louis, MO). All cell cultures were incubated at 37 °C under a 5% CO2 
atmosphere. The following antibodies were used in immunoblotting studies: AR (Sigma-
Aldrich, St. Louis, MO), actin (Cell Signaling Technologies, Danvers, MA). Propidium 
iodide (Calbiochem-Millipore, Darmstadt, Germany) was used in cell cycle experiments, and 
Bortezomib (gift from Ronghu Wu’s lab, Georgia Institute of Technology, Atlanta, GA) was 
used as a protease inhibitor in immunoblotting in addition to RNAse inhibitor (Amresco, 
Solon, OH). DMSO (Sigma-Aldrich, St. Louis, MO), enzalutamide (Cayman Chemical, Ann 
Arbor, MI), and genistein (TCI America, Portland, OR) were used in multiple assays.   
Cell Lines  
1. LNCaP– an androgen dependent prostate cancer cell line 
2. DU145 – an androgen independent prostate cancer cell line 
3. MCF-7 – a hormone (estrogen) sensitive breast cancer cell line 
III. CELL VIABILITY ASSAY 
For all experiments, cells (4,500 cells per well) were grown in 96-well cell culture 
treated microtiter plates (Sigma-Aldrich, St. Louis, MO) with the appropriate compound in 
triplicate for 72 h. An MTS assay (CellTiter 96 Aqueous One Solution, Promega, Madison, 
WI) was used to determine cell viability following manufacturer instructions. Logit plot 
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analysis in GraphPad Prism (GraphPad Software, La Jolla, CA) was used to determine IC50 
values. 
IV. WESTERN BLOT ANALYSIS 
 LNCaP cells (106 cells/dish) were seeded in petri dishes 24 hour prior to treatment 
with various concentrations of compounds for 24h. For the UPS inhibition study, cells were 
incubated with Bortezomib, a protease inhibitor, at 20 nM and 40 nM for 2 hours, prior to 
treatment with the target compounds. Thereafter, media was removed and cells were washed 
with chilled 1X PBS buffer and resuspended in CelLyticM buffer containing a cocktail of 
protease inhibitor (Sigma-Aldrich, St. Louis, MO, USA). Protein concentration was 
determined through Bradford protein assay.  Equal amount of protein was then loaded onto 
an SDS-page gel (Bio-Rad, Hercules, CA, USA) and resolved by electrophoresis at a 
constant voltage of 100 V for 2 h. The gel was transfered onto a nitrocellulose membrane 
and probed for AR, and actin as loading control. 
V. CELL CYCLE ANALYSIS 
LNCaP cells were seeded onto 6-well plates at a density of 1×106 cells in 5 mL of 
media, and incubated in a humidified 5% CO2 atmosphere at 37 °C overnight. Following 
aspiration of media, fresh media containing drugs were added to the cells and incubated 
for 24 h. After incubation, cells were trypsinized, harvested and fixed with 70% EtOH. 
Fixed cells were stained with freshly prepared propidium iodide solution containing 
RNAse A, and then analyzed on flow cytometer (BD FACS Acuri, BD Bioscience, San 
Jose, CA, USA). Unstained cells were used as control. Each experiment was performed 





I would like to sincerely thank Idris Raji for his significant contributions and mentorship 
in the cell and molecular biology components of this project.  
I. SYNTHESIS 
 All target compounds were successfully synthesized. 1H NMR spectra, 13C NMR 
spectra, and mass spectroscopy data can be found in appendices B and C respectively. 
Detailed synthetic methods are also included in appendix A.  
II. CONJUGATE 9B SIGNIFICANTLY REDUCES CANCER CELL VIABILITY 
The antiproliferative potential of the synthesized compounds were evaluated in 
both androgen dependent (LNCaP) and androgen independent (DU145) PCa cells as well 
as in breast cancer cells (MCF-7). A preliminary screen of our compounds in LNCaP and 
DU145 identified conjugate 9b as our lead (data not shown). In LNCaP, genistein 
exhibited an IC50 of 24.02 ± 0.9 µM (Figure 3.1). A combination of enzalutamide and 
genistein did not significantly improve upon the IC50 obtained by genistein, however our 
lead conjugate (9b), exhibited micromolar inhibition of LNCaP with an IC50 of 1.44 ± 0.9 









Figure 3.1 (A) Dose response curve for genistein in LNCaP. (B) Dose response curve for 
genistein in DU145.  
 
Figure 3.2 (A) Dose response curve for genistein, genistein and enzalutamide, and 9b in 
LNCaP. (B) Dose response curve for conjugate 9b at lower concentrations in LNCaP 
with fit line to determine IC50.  
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In DU145, conjugate 9b exhibited an IC50 of 3.38 ± 0.9 µM (Figure 3.3). In 
comparison to a combination of enzalutamide and genistein (IC50 = 31.71 ± 0.8) in 
LNCaP cells as given by Figure 3.4, 9b is significantly more active. The combination of 
enzalutamide and genistein in DU145 cells resulted in dose-dependent activity, however 
50% inhibition was not obtained in the tested concentration range and IC50 values were 
not able to be calculated.  
 With higher concentrations (> 20 µM), 9b was observed to aggregate and 
precipitate out of the culture media in both LNCaP and DU145. As such, a higher 
survival percentage was observed at these concentrations in both cell lines (Figures 3.2 
and 3.3). A similar pattern in cellular toxicity was observed in MCF-7 cells (Figure 3.5), 
which served as a model of hormone-responsive (estrogen) breast cancer.  
 
 
Figure 3.3 (A) Dose response curves for genistein, genistein + enzalutamide, and 9b in 
DU145. (B) Dose response curve for conjugate 9b at lower concentrations in DU145 




Figure 3.4 Dose responsive curves for a combination of genistein and enzalutamide 
(equimolar concentrations at each point) in (A) LNCaP and (B) DU145. 
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Figure 3.5 Dose responsive curves for a combination of genistein and enzalutamide in 









III. CONJUGATE 9B DEGRADES ANDROGEN RECEPTOR IN A DOSE-
DEPENDENT MANNER  
The dose dependent degradation of androgen receptor is observed from the data 
given in Figure 3.6. As exhibited by lanes 2-4, the expression of AR decreases as the 
concentration of conjugate 9b increases from 0.5 µM to 2.5 µM. With the incubation of a 
high concentration (40 µM) of the non-steroidal antiandrogen alkyne component of 
compound 9b (compound 6) in lane 5, the expression of AR was found to be greater than 
that of in lane 4 where cells were treated with 2.5 µM of compound 9b.  
To preliminary examine if UPS inhibition could rescue AR degradation, we 
incubated cells with various concentrations of compound 9b and the proteasome inhibitor 
Bortezomib (lanes 7-9). A comparison between lanes 7 and 8 shows that the same 
concentration of a proteasome inhibitor has a smaller effect (lane 8) on re-expressing AR 
with higher concentrations of compound 9b. The results from lane 9 may be interpreted 
to indicate that a higher concentration of Bortezomib is able to further rescue AR 
expression (in comparison to lane 7), showing that the degradation of AR was likely 
mediated by the ubiquitin protease system. The comparisons in lanes 7-9, however, are 
not very clear due to the quality of the western blot image (Figure 3.6). Therefore, a 
repeat of this experiment with more concentrations of UPS inhibitor and conjugate 9b 
must be carried out to validate the role of the UPS in the degradation of AR.  
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Figure 3.6 Western blot for AR Expression. Lane 1 = DMSO, Lane 2 = 9b (0.5 µM), 
Lane 3 = 9b (1.25 µM), Lane 4 = 9b (2.5 µM), Lane 5 = Compound 6 (40 µM), Lane 6 = 
Genistein (25 µM), Lane 7 = 9b (1.25 µM) + Bortezomib (20 nM, 2 HR incubation), 
Lane 8 = 9b (2.5 µM)  + Bortezomib (20 nM, 2 HR inclubation), Lane 9 = 9b (1.25 µM) 


















IV. COMPOUND 9B INDUCES S-PHASE CELL CYCLE ARREST 
Figure 3.7 shows that treatment with compound 9b results in the shift of the cell 
population percentages to the S phase. Similar profiles were observed regardless of the 
concentration of the lead conjugate in comparison to the DMSO control. Genistein and 
treatment with compound 6 produce similar profiles which also indicated S phase arrest.  
 
Figure 3.7 Cell cycle profiles for LNCaP cells after treatment with (A) DMSO 
[Control], (B) genistein (25 µM), (C) compound 6 (40 µM), (D,E) compound 9b at 2.5 









I. CONJUGATE 9B SIGNIFICANTLY REDUCES CANCER CELL VIABILITY 
 Conjugate 9b was identified as the lead compound in this study after a 
preliminary screen of all the synthesized compounds in PCa cell lines (LNCaP and 
DU145). While all the PEG linker compounds (compounds 9b, 10b, and 11b) exhibit 
inhibition of cell growth in the viability assay for both cell lines (data not shown), 
conjugate 9b (Figures 3.2 and 3.3) is by far the most potent of the three and was therefore 
the focus of the remainder of the study.   
 The inhibition profile obtained for genistein (IC50 = 24.02 ± 0.9 µM) in LNCaP is 
within the range of IC50 values (10 µM to 40 µM) reported in the literature [45, 46]. 
Treatment of genistein in DU145 cells exhibits an inhibitory profile, however an IC50 
value was not able to be calculated with the tested concentration range. In comparison to 
the results obtained from genistein in LNCaP cells, compound 9b is significantly more 
potent. However, at higher concentrations (> 20 µM), the target compound (9b) began to 
precipitate out of the cell media in both LNCaP and DU145 cells (Figure 3.2 and 3.3). 
Since this phenomenon was observed, the cell viability assay was repeated with 
compound 9b at lower concentrations (up to 15 µM) to calculate IC50 values. 
 With a combination of genistein and the FDA approved drug enzalutamide, an 
effective IC50 value of 31.71 ± 0.8 µM was calculated in LNCaP with equimolar 
concentrations of both compounds at every treatment (Figure 3.4). The combinatorial 
treatment of genistein and enzalutamide in DU145 cells exhibits an inhibitory profile, 
however an IC50 value was not able to be calculated with the tested concentration range 
(Figure 3.4). In comparison to genistein alone, a combination of an antiandrogen and 
genistein exhibits less potent inhibition as indicated by a higher IC50 value. However, the 
conjugation of a non-steroidal antiandrogen (an enzalutamide derivative) and genistein 
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via a PEG linker as given by compound 9b significantly outperforms a combinatorial 
treatment of the two agents as separate molecules.   
 The effects of genistein, genistein + enzalutamide, and compound 9b were 
evaluated in estrogen sensitive MCF-7 breast cancer cells to evaluate the effect of the 
target compounds in other hormone-receptor driven cancers (Figure 3.5). This study was 
also done to characterize whether the initial estrogenic effects of genistein that stimulate 
breast cancer growth [47] could be observed in the target compounds. Incubation with 
genistein as well as combinatorial treatment with enzalutamide is found to initially 
increase cancer cell growth, followed by inhibition at higher concentrations (> 20 
µM)shown in Figure 3.5. In contrast, treatment with compound 9b at lower 
concentrations (up to 15 µM) inhibits cancer cell growth. As with LNCaP and DU145, 
the conjugate precipitates out of the cell culture media at higher concentrations (> 20 
µM). Since agonistic behavior is not observed with the lead compound (Figure 3.5), the 
incorporation of the genistein moiety on a bifunctional molecule may reduce the 
estrogenic potential of the group.  
 The selective toxicity of compound 9b was evaluated by comparing the calculated 
IC50 values between LNCaP, an androgen sensitive PCa cell line, and DU145, an 
androgen insensitive PCa cell line representative of CRPC. A lower IC50 value in LNCaP 
(1.44 ± 0.9 µM) in comparison to DU145 (3.37 ± 0.9 µM) indicates that compound 9b is 
more potent in LNCaP compared to DU145. As such, selective toxicity is observed in 
which androgen sensitive PCa cells are more responsive to treatment in comparison to 
androgen insensitive cells.  
 The results of the cell viability assay in PCa cells suggest a link between AR 
expression and drug efficacy for the lead conjugate. As such, the effect of the lead 
compound on the expression of androgen receptor was evaluated via western 
immunoblotting with a protocol adapted from Gustafson and colleagues [14].  
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II. CONJUGATE 9B DEGRADES ANDROGEN RECEPTOR IN A DOSE-
DEPENDENT MANNER 
As shown in Figure 3.6, the dose-dependent degradation of androgen receptor is 
observed with increasing concentrations of conjugate 9b. The secondary component of 
this study sought to link the degradation of AR to the ubiquitin protease system. The 
incubation of LNCaP cells with Bortezomib, a UPS inhibitor should theoretically rescue 
AR expression if UPS mediated degradation is the primary means of downregulation in 
the cells.  However, the results from the western blot were not clear enough to be 
conclusive. Nevertheless, this data may be interpreted as a preliminary study that shows 
the strong possibility that the observed AR degradation could be UPS mediated. Further 
studies are currently planned in the future to generate a clearer western blot image by 
varying the concentration range of the target compound and test other UPS inhibitors 
such as epoxomycin.  
III. COMPOUND 9B INDUCES S-PHASE CELL CYCLE ARREST
The results of the cell cycle study (Figure 3.7) indicate that the target compound 
induces S-phase arrest in comparison to the control. While these results also indicate that 
genistein also induces S-phase arrest, several sources in the literature report that G2/M 
and G1 arrest was the primary mode of cell cycle arrest in LNCaP (and other) cells 
incubated with genistein [46, 48, 49]. Since the experimental results of this study are in 
conflict with those reported in the literature, a follow up study of this assay must be 
performed to confirm that S-phase arrest is indeed occurring in LNCaP cells treated with 
genistein and the target compounds.  
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IV. CONCLUSIONS 
This study explored the efficacy of a bifunctional molecule; specifically a 
combination of a potent antiandrogen and genistein on the growth of various prostate and 
breast cancer cells as well as the extent of UPS mediated AR degradation. Preliminary 
cell viability studies have identified a promising lead compound (compound 9b) within 
the synthesized conjugates. This compound exhibits potent inhibition of cell growth in 
androgen insensitive LNCaP cells (IC50 = 1.44 ± 0.9 µM), androgen insensitive DU145 
cells (IC50 = 3.38 ± 0.9 µM). Western immunoblotting studies confirmed the dose-
dependent degradation of AR and cell cycle analyses indicate S-phase arrest with the 
treatment of compound 9b. While preliminary immunoblotting studies suggest the 
degradation of AR is mediated by the ubiquitin protease system (UPS), further studies 
must be carried out to validate these preliminary results.  
V. FUTURE DIRECTIONS 
As mentioned previously in the discussion, western immunoblotting studies will 
need to be repeated with various concentrations of conjugate 9b as well as the 
incorporation of other UPS inhibitors such as epoxomycin. The cell cycle study must also 
be repeated to confirm whether the observed results truly conflict with the established 
literature for the effect of genistein on LNCaP cells. In addition to these required studies, 
androgen receptor binding studies will also need to be carried out on all the synthesized 
target compounds to characterize the effect of adding the genistein moiety on the binding 
affinity of the antiandrogen to AR. Matrigel invasion chamber assays may also be 
performed to study the effect of the target compounds on the metastatic potential of PC3 
PCa cells.  
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APPENDIX A  
SUPPLEMENTARY INFORMATION  
I. SYNTHETIC PROTOCOLS 
Synthesis of 7-(2-azidoethoxy)-5-hydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one (3) 
1 (0.5 g, 0.9 mmol) and 2 (0.56 g, 2.33 mmol) were 
dissolved in DMF (25 mL). The mixture was reacted 
overnight at 50° C. The product was purified via column chromatography 5% Acetone: 
95% DCM. The product was yielded as a white solid. (232.5 mg, 70.2 %). 1H NMR (400 
MHz, dmso) δ 12.97 (d, J = 6.3 Hz, 1H), 9.64 (s, 1H), 8.42 (s, 1H), 7.48 – 7.33 (m, 2H), 
6.90 – 6.79 (m, 2H), 6.69 (d, J = 2.3 Hz, 1H), 6.42 (d, J = 2.3 Hz, 1H), 4.34 – 4.25 (m, 
2H), 3.74 – 3.66 (m, 2H). MS (ESI) m/z calculated C17H13O5N3 [M+H
+]: 339.09, found 
339.17.  
Synthesis of 7-((23-azido-3,6,9,12,15,18,21-heptaoxatricosyl)oxy)-5-hydroxy-3-(4-
hydroxyphenyl)-4H-chromen-4-one (5).  
1 (0.270 g, 0.525 mmol), 4 (0.318 g, 0.575 mmol) and 
KI (0.01 g, 0.05 mmol) were dissolved in 5 mL of DMF. 
The mixture was reacted overnight at 100° C. The 
product was purified via preparative TLC (1:3 Acetone/DCM and eluent: 2:3 
Acetone/DCM). The product was obtained as a pale yellow oil. (330 mg, 96.9 %). 1H 
NMR (400 MHz, cdcl3) δ 12.83 (s, 1H), 8.01 (s, 1H), 7.77 (s, 1H), 7.38 – 7.30 (m, 2H), 
6.92 – 6.85 (m, 2H), 6.32 (q, J = 2.3 Hz, 2H), 4.11 – 4.03 (m, 2H), 3.87 – 3.81 (m, 2H), 
3.74 – 3.67 (m, 4H), 3.67 – 3.62 (m, 22H), 3.40 – 3.34 (m, 2H). HRMS (ESI) m/z 
calculated for C39H30O6N6F3S [M+H







6 (100 mg, 0.26 mmol), 3 (89.9 mg, 0.26 mmol), and DIPEA (59.93 mg, 0.46 mmol) 
were dissolved in anhydrous DMSO under argon. Copper (I) Iodide (25.23 mg, 0.13 
mmol) was added and the reaction mixture was stirred under argon at ambient 
temperature overnight. The reaction was diluted with DCM and washed with 1:4 
NH4OH/Saturated NH4Cl (3x30 mL) and saturated NH4Cl (30 mL) and the organic layer 
was dried under sodium sulfate, filtered and concentrated in vacuo. Column 
chromatography (eluent 80:4:1 – DCM: Acetone: MeOH) gave the product as an orange-
white solid. (105.3 mg, 56 %). 1H NMR (400 MHz, dmso) δ 12.93 (s, 1H), 9.61 (s, 1H), 
8.28 (d, J = 8.4 Hz, 1H), 8.17 (d, J = 2.0 Hz, 1H), 8.01 (dd, J = 8.4, 1.6 Hz, 1H), 7.94 (s, 
1H), 7.42 – 7.33 (m, 2H), 6.85 – 6.77 (m, 2H), 6.65 (d, J = 2.3 Hz, 1H), 6.38 (d, J = 2.3 
Hz, 1H), 4.74 (t, J = 4.9 Hz, 2H), 4.51 (t, J = 4.9 Hz, 2H), 3.33 (s, 6H), 2.67 (s, 2H), 1.64 
(s, 5H), 1.41 (s, 7H). 13C NMR (101 MHz, dmso) δ 180.9, 175.1, 164.1, 162.2, 157.9, 
157.8, 155.0, 152.9, 147.1, 136.5, 130.7, 130.4, 123.0, 115.5, 106.1, 98.9, 93.4, 67.5, 
62.0, 31.2, 28.8, 26.7, 25.0, 22.9. HRMS (ESI) m/z calculated for C36H32O7N6F3 [M+H
+]: 






7 (121 mg, 1 mmol), 3 (100 mg, 1 mmol), and DIPEA (66 mg, 1.75 mmol) were 
dissolved in anhydrous DMSO under argon. Copper (I) Iodide (28 mg, 0.5 mmol) was 
added and the reaction mixture was stirred under argon at ambient temperature overnight. 
The reaction was diluted with DCM and washed with 1:4 NH4OH/Saturated NH4Cl (3x30 
mL) and saturated NH4Cl (30 mL) and the organic layer was dried under sodium sulfate, 
filtered and concentrated in vacuo. Column chromatography (eluent 80:4:1 – DCM: 
Acetone: MeOH) gave the product as a white solid. (141.1 mg, 77.4%). 1H NMR (400 
MHz, dmso) δ 12.95 (s, 1H), 9.60 (s, 1H), 8.76 (s, 1H), 8.39 (d, J = 11.0 Hz, 2H), 8.31 (s, 
1H), 8.09 (d, J = 8.3 Hz, 1H), 8.04 (d, J = 8.6 Hz, 2H), 7.46 (d, J = 8.6 Hz, 2H), 7.38 (d, 
J = 8.7 Hz, 2H), 6.81 (d, J = 8.8 Hz, 2H), 6.72 (d, J = 2.3 Hz, 1H), 6.47 (d, J = 2.2 Hz, 
1H), 5.74 (s, 1H), 4.88 (s, 2H), 4.60 (s, 2H), 3.33 (s, 6H). 13C NMR (101 MHz, dmso) δ 
180.9, 180.4, 175.5, 164.1, 162.3, 157.9, 146.1, 138.6, 136.6, 135.2, 134.5, 132.0, 130.9, 
130.6, 126.7, 123.2, 123.0, 121.5, 115.5, 106.2, 105.0, 93.5, 66.9, 60.2, 31.2, 23.4. 
HRMS (ESI) m/z calculated for C38H28O6N6F3S [M+H






yl)-2-(trifluoromethyl)benzonitrile (11a)  
 
8 (25 mg, 0.06 mmol), 3 (19.86 mg, 0.06 mmol), and DIPEA (12.9 mg, 0.1 mmol) were 
dissolved in anhydrous DMSO under argon. Copper (I) Iodide (5.57 mg, 0.03 mmol) was 
added and the reaction mixture was stirred under argon at ambient temperature overnight. 
The reaction was diluted with DCM and washed with 1:4 NH4OH/Saturated NH4Cl (3x30 
mL) and saturated NH4Cl (30 mL) and the organic layer was dried under sodium sulfate, 
filtered and concentrated in vacuo. Column chromatography (eluent 80:4:1 – DCM: 
Acetone: MeOH) gave the product as a white solid. (51.5 mg, 87.1%).  
1H NMR (400 MHz, dmso) δ 12.98 (s, 1H), 9.65 (s, 1H), 8.70 (s, 1H), 8.47 – 8.34 (m, 
2H), 8.14 (d, J = 8.4 Hz, 1H), 7.86 (d, J = 8.2 Hz, 2H), 7.59 (d, J = 8.5 Hz, 2H), 7.41 (d, J 
= 8.7 Hz, 2H), 6.84 (d, J = 8.6 Hz, 2H), 6.49 (s, 1H), 5.16 (s, 2H), 4.88 (s, 2H), 4.61 (s, 









Synthesis of  4-(3-(4-(1-(23-((5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-
yl)oxy)-3,6,9,12,15,18,21-heptaoxatricosyl)-1H-1,2,3-triazol-4-yl)butyl)-4,4-dimethyl-
2,5-dioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (9b)  
 
6 (52.4 mg, 0.138 mmol), compound 5 (90 mg, 0.138 mmol), and DIPEA (31.4 mg, 
0.241 mmol) were dissolved in anhydrous DMSO under argon. Copper (I) Iodide (13.2 
mg, 0.07 mmol) was added and the reaction mixture was stirred under argon at ambient 
temperature overnight. The reaction was diluted with DCM and washed with 1:4 
NH4OH/Saturated NH4Cl (3x30 mL) and saturated NH4Cl (30 mL) and the organic layer 
was dried under sodium sulfate, filtered and concentrated in vacuo. Column 
chromatography (eluent 80:4:1 – DCM: Acetone: MeOH) gave the product. The product 
was lyophilized and gave a yellow oil. (15.2 mg, 12.8 %). 1H NMR (400 MHz, cdcl3) δ 
12.83 (s, 1H), 8.11 (s, 1H), 7.97 (d, J = 10.0 Hz, 1H), 7.87 (d, J = 8.4 Hz, 1H), 7.78 (s, 
1H), 7.52 (s, 1H), 7.31 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.5 Hz, 2H), 6.32 (dd, J = 12.4, 
2.2 Hz, 2H), 5.28 (s, 1H), 4.48 (s, 2H), 4.10 (s, 2H), 3.82 (s, 4H), 3.60 (t, J = 10.2 Hz, 
23H), 3.35 (s, 2H), 2.75 (s, 2H), 2.61 (s, 2H), 1.75 (s, 4H), 1.48 (s, 5H). 13C NMR (101 
MHz, cdcl3) δ 180.8, 174.7, 164.6, 162.5, 157.8, 157.2, 152.8, 152.6, 136.5, 135.2, 130.0, 
127.9, 123.7, 122.9, 121.9, 115.7, 115.0, 106.2, 98.7, 92.9, 70.8, 70.6, 70.5, 70.4, 69.5, 
69.3, 68.0, 61.9, 50.3, 40.1, 28.9, 26.8, 25.0, 23.5. HRMS (ESI) m/z calculated for 
C50H60O14N6F3 [M+H
+]: 1025.4104, found 1025.4114. 
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7 (35.8 mg, 0.086 mmol), 5 (71.2 mg, 0.11 mmol), and DIPEA (18 mg, 0.14 mmol) were 
dissolved in anhydrous DMSO under argon. Copper (I) Iodide (8.1 mg, 0.043 mmol) was 
added and the reaction mixture was stirred under argon at ambient temperature overnight. 
The reaction was diluted with DCM and washed with 1:4 NH4OH/Saturated NH4Cl (3x30 
mL) and saturated NH4Cl (30 mL) and the organic layer was dried under sodium sulfate, 
filtered and concentrated in vacuo. Column chromatography (eluent 80:4:1 – DCM: 
Acetone: MeOH) gave the product.  The product was lyophilized and an orange-white 
solid was obtained.  (28.3 mg, 30.7 %). 1H NMR (400 MHz, cdcl3) δ 12.83 (s, 1H), 8.12 
(s, 1H), 7.99 (d, J = 16.0 Hz, 4H), 7.85 (d, J = 8.4 Hz, 1H), 7.76 (s, 1H), 7.40 – 7.29 (m, 
4H), 6.90 (d, J = 8.5 Hz, 2H), 6.31 (d, J = 3.0 Hz, 2H), 4.60 (s, 2H), 4.07 (s, 2H), 3.90 (s, 
2H), 3.81 (s, 2H), 3.63 (t, J = 20.5 Hz, 22H), 3.48 (s, 1H), 1.60 (s, 4H), 1.25 (s, 1H). 13C 
NMR (101 MHz, cdcl3) δ 179.9, 178.8, 174.0, 163.8, 161.6, 157.0, 155.9, 152.0, 145.2, 
136.1, 134.4, 133.3, 132.7, 131.8, 131.6, 129.0, 125.9, 122.5, 121.4, 121.1, 119.7, 114.9, 
113.7, 109.2, 105.2, 97.6, 91.9, 69.3, 68.2, 67.0, 65.6, 49.5, 22.9. HRMS (ESI) m/z 
calculated for C52H56O13N6F3S [M+H





5-oxo-2-thioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile (11b)  
 
8 (25 mg, 0.06 mmol), compound 5 (38.5 mg, 0.06 mmol), and DIPEA (12.9 mg, 0.1 
mmmol) were dissolved in anhydrous DMSO under argon. Copper (I) Iodide (5.57 mg, 
0.03 mmol) was added and the reaction mixture was stirred under argon at ambient 
temperature overnight. The reaction was diluted with DCM and washed with 1:4 
NH4OH/Saturated NH4Cl (3x30 mL) and saturated NH4Cl (30 mL) and the organic layer 
was dried under sodium sulfate, filtered and concentrated in vacuo. Purification with 
preparative TLC (eluent 80:4:1 – DCM: Acetone: MeOH) gave the product. The product 
was lyophilized and this gave a red-orange solid. (22.1 mg, 34.3 %) 1H NMR (400 MHz, 
cdcl3) δ 12.83 (s, 1H), 8.04 (s, 1H), 8.00 – 7.92 (m, 2H), 7.83 (d, J = 7.9 Hz, 3H), 7.77 (s, 
1H), 7.47 (d, J = 7.6 Hz, 2H), 7.32 (d, J = 8.4 Hz, 2H), 6.91 (d, J = 8.4 Hz, 2H), 6.32 (dd, 
J = 6.6, 2.1 Hz, 2H), 5.29 (s, 2H), 5.13 (s, 2H), 4.58 (s, 2H), 4.08 (s, 2H), 3.89 (s, 2H), 
3.82 (s, 2H), 3.60 (t, J = 8.9 Hz, 23H), 1.46 (s, 5H), 1.24 (s, 1H). 13C NMR (101 MHz, 
cdcl3) δ 180.8, 179.9, 175.4, 164.6, 162.5, 157.8, 156.8, 152.7, 137.3, 135.9, 135.2, 
132.2, 130.7, 130.1, 128.3, 127.1, 126.2, 123.2, 122.2, 115.7, 114.8, 110.0, 106.2, 98.7, 
92.9, 70.8, 70.6, 70.5, 69.4, 69.3, 67.9, 65.4, 50.5, 47.3, 23.7. HRMS (MALDI) m/z 
calculated for C53H58O13N6F3S [M+H
+]: 1075.37, found 1075.3735. 
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APPENDIX B 
1H NMR AND 13C NMR SPECTRA 
 
















































































































1H NMR (400 MHz, dmso) δ 12.93 (s, 1H), 9.61 (s, 1H), 8.28 (d, J = 8.4 
Hz, 1H), 8.17 (d, J = 2.0 Hz, 1H), 8.01 (dd, J = 8.4, 1.6 Hz, 1H), 7.94 (s, 1H), 
7.42 – 7.33 (m, 2H), 6.85 – 6.77 (m, 2H), 6.65 (d, J = 2.3 Hz, 1H), 6.38 (d, J 
= 2.3 Hz, 1H), 4.74 (t, J = 4.9 Hz, 2H), 4.51 (t, J = 4.9 Hz, 2H), 3.33 (s, 6H), 
2.67 (s, 2H), 1.64 (s, 5H), 1.41 (s, 7H).

























































































13C NMR (101 MHz, dmso) δ 180.90, 175.11, 164.12, 162.18, 157.93, 157.84, 154.95, 152.93, 147.11, 
136.45, 130.67, 130.36, 123.02, 115.50, 106.13, 98.93, 93.42, 67.51, 62.02, 31.15, 28.84, 26.74, 24.97, 
22.93.






























































































1H NMR (400 MHz, dmso) δ 12.95 (s, 1H), 9.60 (s, 1H), 8.76 (s, 1H), 8.39 (d, J = 11.0 Hz, 2H), 8.31 (s, 
1H), 8.09 (d, J = 8.3 Hz, 1H), 8.04 (d, J = 8.6 Hz, 2H), 7.46 (d, J = 8.6 Hz, 2H), 7.38 (d, J = 8.7 Hz, 2H), 
6.81 (d, J = 8.8 Hz, 2H), 6.72 (d, J = 2.3 Hz, 1H), 6.47 (d, J = 2.2 Hz, 1H), 5.74 (s, 1H), 4.88 (s, 2H), 4.60 
(s, 2H), 3.33 (s, 6H).
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13C NMR (101 MHz, dmso) δ 180.89, 180.37, 175.47, 164.10, 162.28, 157.93, 146.08, 138.55, 136.62, 
135.18, 134.51, 132.00, 130.85, 130.64, 126.70, 123.15, 123.04, 121.49, 115.51, 106.21, 105.04, 93.50, 
66.87, 60.20, 31.17, 23.42.
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1H NMR (400 MHz, dmso) δ 12.98 (s, 1H), 9.65 (s, 1H), 8.70 (s, 1H), 8.47 – 8.34 (m, 2H), 8.14 (d, J =
8.4 Hz, 1H), 7.86 (d, J = 8.2 Hz, 2H), 7.59 (d, J = 8.5 Hz, 2H), 7.41 (d, J = 8.7 Hz, 2H), 6.84 (d, J = 8.6 
Hz, 2H), 6.49 (s, 1H), 5.16 (s, 2H), 4.88 (s, 2H), 4.61 (s, 2H), 3.37 (s, 16H).
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1H NMR (400 MHz, cdcl3) δ 12.83 (s, 1H), 8.11 (s, 1H), 7.97 (d, J = 10.0 Hz, 1H), 7.87 (d, J = 8.4 Hz, 
1H), 7.78 (s, 1H), 7.52 (s, 1H), 7.31 (d, J = 8.5 Hz, 2H), 6.90 (d, J = 8.5 Hz, 2H), 6.32 (dd, J = 12.4, 2.2 
Hz, 2H), 5.28 (s, 1H), 4.48 (s, 2H), 4.10 (s, 2H), 3.82 (s, 4H), 3.60 (t, J = 10.2 Hz, 23H), 3.35 (s, 2H), 
2.75 (s, 2H), 2.61 (s, 2H), 1.75 (s, 4H), 1.48 (s, 5H).
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1H NMR (400 MHz, cdcl3) δ 12.83 (s, 1H), 8.12 (s, 1H), 7.99 (d, J = 16.0 Hz, 4H), 7.85 (d, J = 8.4 Hz, 
1H), 7.76 (s, 1H), 7.40 – 7.29 (m, 4H), 6.90 (d, J = 8.5 Hz, 2H), 6.31 (d, J = 3.0 Hz, 2H), 4.60 (s, 2H), 
4.07 (s, 2H), 3.90 (s, 2H), 3.81 (s, 2H), 3.63 (t, J = 20.5 Hz, 22H), 3.48 (s, 1H), 1.60 (s, 4H), 1.25 (s, 1H).
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13C NMR (101 MHz, cdcl3) δ 179.94, 178.81, 173.97, 163.84, 161.55, 157.01, 155.87, 151.95, 145.15, 
136.05, 134.38, 133.25, 132.71, 131.81, 131.58, 128.98, 125.91, 122.51, 121.38, 121.07, 119.70, 114.86, 
113.73, 109.18, 105.23, 97.61, 91.93, 69.31, 68.17, 67.04, 65.60, 49.52, 22.91.
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1H NMR (400 MHz, cdcl3) δ 12.83 (s, 1H), 8.04 (s, 1H), 8.00 – 7.92 (m, 2H), 7.83 (d, J = 7.9 Hz, 3H), 
7.77 (s, 1H), 7.47 (d, J = 7.6 Hz, 2H), 7.32 (d, J = 8.4 Hz, 2H), 6.91 (d, J = 8.4 Hz, 2H), 6.32 (dd, J = 6.6, 
2.1 Hz, 2H), 5.29 (s, 2H), 5.13 (s, 2H), 4.58 (s, 2H), 4.08 (s, 2H), 3.89 (s, 2H), 3.82 (s, 2H), 3.60 (t, J = 
8.9 Hz, 23H), 1.46 (s, 5H), 1.24 (s, 1H).
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Appendix B - Compound 11(b) - 13C NMR
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APPENDIX C 
MASS SPECTROSCOPY DATA 
This appendix contains mass spectroscopy data from all target compounds. 
YO140826-02 #79-112 RT: 1.86-2.65 AV: 34 NL: 1.33E7
T: FTMS + p ESI Full ms [150.00-2000.00]
























































Appendix C - Compound 9(a)
Page 42
YO140826-04 #81-120 RT: 1.91-2.84 AV: 40 NL: 2.56E6
T: FTMS + p ESI Full ms [150.00-2000.00]


































































Appendix C - Compound 10(a)
Page 43
YO140911-02 #230-302 RT: 1.95-2.54 AV: 73 NL: 9.53E6
T: FTMS + p ESI Full ms [150.00-2000.00]

















































Appendix C - Compound 11(a)
Page 44
YO141023-01 #74-117 RT: 1.73-2.74 AV: 44 NL: 1.05E8
T: FTMS + p ESI Full ms [150.00-2000.00]

















































Appendix C - Compound 9(b)
Page 45
YO141023-02 #82-127 RT: 1.93-3.01 AV: 46 NL: 1.26E7
T: FTMS + p ESI Full ms [150.00-2000.00]

















































Appendix C - Compound 10(b)
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Appendix C - Compound 11(b) 
4 7 0 0  R  e f le c t o r  Sp e c  # 1  M C  [ B  P  =  1 0 7 5 .2 ,  8 4 6 0 ]
Ge o rg e  AGI-3 4  (d ith ra n o l)
1075.2
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